Overview of the therapeutic strategies for ER positive breast cancer.

doi:10.1016/j.bcp.2023.115552

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Overview of the therapeutic strategies for ER positive breast cancer.

Biochemical pharmacology - 1 Jun 2023

Blakely Brianna, Shin Seobum, Jin Kideok

Abstract excerpt

Estrogen Receptor is the driving transcription factor in about 75% of all breast cancers, which is the target of endocrine therapies, but drug resistance is a common clinical problem. ESR1 point mutations at the ligand binding domain are frequently identified in metastatic tumor and ctDNA (Circulating tumor DNA) derived from ER positive breast cancer patients with endocrine therapies. Although endocrine therapy...

Topics

Humans
Female
Breast Neoplasms
Estrogen Receptor alpha
Drug Resistance, Neoplasm
Receptors, Estrogen
Point Mutation
Mutation
Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 37068524
DOI: 10.1016/j.bcp.2023.115552
PMCID: PMC10394654

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics